Transporter-mediated efflux influences CNS side effects: ABCB1, from antitarget to target

Molecular Informatics

Volumn 29, Issue 1-2, 2010, Pages 16-26

  Broccatelli, Fabio ^a   Carosati, Emanuele ^a   Cruciani, Gabriele ^a   Oprea, Tudor I ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

ABCB1; Antidepressants; Antihistamines; Antipsychotics; CNS permeability; Data mining; LogP; MRTD

Indexed keywords

ALCOHOLS; DRUG DOSAGE; DRUG INTERACTIONS;

ABCB1; ANTIDEPRESSANT; ANTIHISTAMINE; ANTIPSYCHOTIC; CNS PERMEABILITY; HISTAMINES; LOGP; MRTD; PASSIVE DIFFUSIONS; SIDE EFFECT;

DATA MINING;

ACRIVASTINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ARIPIPRAZOLE; AZELASTINE; BENZATROPINE; CLEMASTINE; CLOZAPINE; COCAINE; CYPROHEPTADINE; DESLORATADINE; EBASTINE; EPINASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST; ILOPERIDONE; LEVOCETIRIZINE; MEBHYDROLIN; MIZOLASTINE; MULTIDRUG RESISTANCE PROTEIN 1; NEUROLEPTIC AGENT; OLANZAPINE; OXATOMIDE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZIPRASIDONE;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; DIFFUSION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TRANSPORT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEMBRANE PERMEABILITY; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PH; PREDICTION; PRIORITY JOURNAL; PROTEIN TARGETING; PROTEIN TRANSPORT; RECEPTOR AFFINITY; REVIEW; SEDATION;

EID: 77952641150     PISSN: 18681743     EISSN: 18681751     Source Type: Journal    
DOI: 10.1002/minf.200900075     Document Type: Review

References (56)

1. T. Olsson, T. I. Oprea, Curr. Opin. Drug Discov. Develop. 2001, 4, 308-313.
2. Antitargets (Eds: R. Vaz, T. Klabunde), Wiley-VCH, Weinheim, 2008, p. 480.
3. C. P. Austin, L. S. Brady, T. R. Insel, F. S. Collins, Science 2004, 306, 1138-1139.
4. PubChem is available online at the National Center for Biotechnology Information, http://pubchem.ncbi.nlm.nih.gov/
5. Chembldb is available online from the European Bioinformatics Institute, http://www.ebi.ac.uk/chembldb/index.php
6. T. I. Oprea, A. Tropsha, Drug Discov. Today Technol. 2006, 3, 357-365.
7. M. Yamashita, H. Fukui, K. Sugama, Y. Horio, S. Ito, H. Mizuguchi, H. Wada, Proc. Natl. Acad. Sci. USA 1991, 88, 11515-11519.
8. R. L. Juliano, V. Ling, Biochim. Biophys. Acta 1976, 455, 152-162.
9. C.-J. Chen, J. E. Chin, K. Ueda, D. P. Clark, I. Pastan, M. M. Gottesman, I. B. Roninson, Cell 1986, 47, 381-389.
10. M. B. Emanuel, Clin. Exper. Allergy 1999, 29 (Suppl 3), 1-11.
11. T. T. Quach, A. M. Duchemin, C. Rose, J. C. Schwartz, Eur. J. Pharmacol. 1979, 60, 391-392.
12. I. Hindmarch, Z. Shamsi, Clin. Exper. Allergy 1999, 29 (Suppl 3), 133-142.
13. H. Timmerman, in Analogue-based Drug Discovery (Eds: J. Fischer, C. R. Ganellin), Wiley-VCH, Weinheim, 2006, pp. 401-418.
14. K. Yanai, N. Okamura, M. Tagawa, M. Itoh, T. Watanabe, Clin. Exper. Allergy 1999, 29 (Suppl 3), 29-36.
15. M. Mathews, D. J. Muzina, Cleve Clin. J. Med. 2007, 74, 597-606.
16. B. Cusack, A. Nelson, E. Richelson, Psychopharmacology 1994, 114, 559-565.
17. A. H. Schinkel, J. W. Jonker, Adv. Drug Deliv. Rev. 2003, 55, 3-29.
18. L. Z. Benet, Mol. Pharmaceutics 2009, 6, 1631-1643.
19. L. Z. Benet, C.-Y. Wu, M. F. Hebert, V. J. Wacher, J. Controlled Release 1996, 39, 139-143.
20. G. D. Leonard, T. Fojo, S. E. Bates, Oncologist 2003, 8, 411-424
21. M. Wada, Cancer. Lett. 2006, 234, 40-50
22. M. Chishty, A. Reichelt, J. Siva, N. J. Abbott, D. J. Begley, J. Drug Targeting 2001, 9, 223-228.
23. C. Hansch, J. P. Björkroth, A. Leo, J. Pharm. Sci. 1987, 79, 663-687.
24. A. Leo, Chem. Rev. 1993, 93, 1281-1306.
25. A. M. ter Laak, R. S. Tsai, G. M. Donné-op den Kelder, P.-A. Carrupt, B. Testa, H. Timmerman, Eur. J. Pharm. Sci. 1994, 2, 373-384.
26. C. Chen, H. Hanson, J. W. Watson, Drug Metab. Dispos. 2003, 31(3), 312-318.
27. Anonymous, Clin. Exper. Allergy 1999, 29 (Suppl 3), 37-38.
28. H. Timmerman, 2007, personal communication.
29. The following resources were used to annotate 'sedation' and 'orthostatic hypotension': Clarke's Analysis of Drugs and Poisons, http://www. medicinescomplete.com/mc/clarke/current/;DailyMed, http://dailymed.nlm.nih.gov/ dailymed/about.cfm;Drugs@FDA, http://www.accessdata.fda.gov/Scripts/cder/ DrugsatFDA/; European Medicines Agency, http://www.emea.europa.eu/htms/human/ epar/a.htm; Martindale http://www.medicinescomplete.com/mc/martindale/current/; Medicines UK, http://www.medicines.org.uk/; and the Swedish Pharmacopeia (FASS; in Swedish), http://www.fass.se/LIF/home/index.jsp. Note: to access Clarke's and Martindale, a subscription license is required.
30. M. Olah, R. Rad, L. Ostopovici, A. Bora, N. Hadaruga, D. Hadaruga, R. Moldovan, A. Fulias, M. Mracec, T. I. Oprea, in Chemical Biology: From Small Molecules to Systems Biology and Drug Design, Vol.2 (Eds: S. L. Schreiber, T. M. Kapoor, G. Wess), Wiley-VCH, Weinheim, 2007, pp. 760-786.
31. The following resources were used to annotate target bioactivity: IUPHAR-DB, http://www.iuphar-db.org/; PDSP, http://pdsp.med.unc.edu/pdsp.php; GPCR-DB, http://www.gpcr.org/7tm/data/.
32. J. E. Leysen, W. Gommeren, A. Eens, D. de Chafoy de Courcelles, J. C. Stoof, P. A. J. Janssen, J. Pharmacol. Exp. Ther. 1988, 247, 661-670.
33. J. E. Leysen, P. M. F. Janssen, A. Schotte, W. H. M. L. Luyten, A. A. H. P. Megens, Psychopharmacology 1993, 112, S40-S54.
34. M. J. Dewan, M. Koss, Acta Psychiatr. Scand. 1995, 91, 229-232.
35. M. Tatsumi, K. Groshan, R. D. Blakely, E. Richelson, Eur. J. Pharmacol. 1997, 340, 249-258.
36. C. Sánchez, J. Hyttel, Cell Mol. Neurobiol. 1999, 19, 467-489.
37. R. Leurs, M. K. Church, M. Taglialatela, Clin. Exp. All. 2002, 32, 489-498.
38. M. Gillard, B. Christophe, B. Wels, M. Peck, R. Massingham, P. Chatelain, Inflamm. Res. 2003, 52 (Suppl. 1), S49-S50.
39. A. J. Harmar, R. A. Hills, E. M. Rosser, M. Jones, O. P. Buneman, D. R. Dunbar, S. D. Greenhill, V. A. Hale, J. L. Sharman, T. I. Bonner, W. A. Catterall, A. P. Davenport, P. Delagrange, C. T. Dollery, S. M. Foord, G. A. Gutman, V. Laudet, R. R. Neubig, E. H. Ohlstein, R. W. Olsen, J. Peters, J.-P. Pin, R. R. Ruffolo, D. B. Searls, M. W. Wright, M. Spedding, Nucl. Acids Res. 2009, 37, D680-D685.
40. S. Whitebread, J. Hamon, D. Bojanic, L. Urban, Drug Discov. Today 2005, 10, 1421-1433.
41. K. Popper, Conjectures and Refutations, Routledge and Keagan Paul, London, 1963, pp. 33-39.
42. A. H. Schinkel, E. Wagenaar, C. A. A. M. Mol, L. van Deemter, J. Clin. Invest. 1996, 97, 2517-2524.
43. W. Neuhaus, C. R. Noe, in Transporters as Drug Carriers (Eds: G. Ecker, P. Chiba), Wiley-VCH, Weinheim, 2009, pp. 263-298.
44. D. J. Begley, in Efflux Transporters and the Blood-Brain Barrier (Ed: E. M. Taylor), Nova Science Publishers, New York, 2005, pp. 107-135.
45. J. W. Polli, S. A. Wring, J. E. Humphreys, J. E. Huang, J. B. Morgan, L. O. Webster, C. J. Serabjit-Singh, J. Pharmacol. Exp. Ther. 2001, 299, 620-628.
46. K. M. Mahar Doan, J. E. Humphreys, L. O. Webster, S. A. Wring, L. G. Shampine, C. J. Serabjit-Singh, K. K. Adkinson, J. W. Polli, J. Pharmacol. Exp. Ther. 2002, 303, 1029-1037.
47. M. V. S. Varma, K. Sateesh, R. Panchagnula, Mol. Pharmaceutics 2005, 2, 12-21.
48. B. Feng, J. B. Mills, R. E. Davidson, R. J. Mireles, J. S. Janiszewski, M. D. Troutman, S. M. de Morais, Drug Metab. Dispos. 2008, 36, 268-275.
49. E. J. Matthews, N. L. Kruhlak, R. D. Benz, J. F. Contrera, Curr. Drug Discov. Technol. 2004, 1, 61-76.
50. S. G. Summerfield, A. J. Stevens, L. Cutler, M. C. Osuna, B. Hammond, S.-P. Tang, A. Hersey, D. J. Spalding, P. Jeffrey, J. Pharmacol. Exp. Ther. 2006, 316, 1282-1290.
51. K. Brøsen, R. Klysner, L. F. Gram, S. V. Otton, P. Bech, L. Bertilsson, Eur. J. Clin. Pharmacol. 1986, 30, 679-684.
52. The FDA label for Xyzal® (levocetirizine) is available online from the National Library of Medicine, http://dailymed.nlm.nih.gov/dailymed/drugInfo. cfm?id=7522
53. S. Boyer, 2009, personal communication.
54. M. Cases, J. Mestres, Drug Discov. Today 2009, 14, 479-485.
55. P. Crivori, in Antitargets (Eds: R. Vaz, T. Klabunde), Wiley-VCH, Weinheim, 2008, pp. 367-397.
56. A. J. Sadeque, C. Wendel, H. He, S. Shah, A. J. Wood, Clin. Pharmacol. Ther. 2000, 68, 231-237.